Presentations by Event

Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β–lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β–lactamases

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs, ID Week 2017

Program(s): durlobactam (etx2514)

Cefpodoxime proxetil/ETX0282: A novel oral β-lactam/β-lactamase inhibitor combination to treat the emerging threat of multi-drug resistant Enterobacteriaceae

John O’Donnell, ASM Microbe 2017

Program(s): etx0282

The Antibacterial Activity of Sulbactam and the Novel β–lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem Against Recent Clinical Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa

Sarah McLeod, ASM Microbe 2017

Program(s): durlobactam (etx2514)

The Antibacterial Activity of Cefpodoxime and the Novel β–lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of β–lactamase-producing Enterobacteriaceae

Sarah McLeod, ASM Microbe 2017

Program(s): etx0282

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

Thomas Durand-Reville, ASM Microbe 2017

Program(s): etx0282

Reversibility of β–lactamase inhibition by the broad-spectrum diazabicyclooctenone serine β–lactamase inhibitor ETX2514

Adam Shapiro, ASM Microbe 2017

Program(s): durlobactam (etx2514)

ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens

Ruben Tommasi, ECCMID 2017

Program(s): durlobactam (etx2514)

ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo

Alita Miller, ECCMID 2017

Program(s): durlobactam (etx2514)